Sweat was collected with the PharmChek TM sweat patch and drugs were eluted from the collection pad of the patch. A solid phase, enzyme immunoassay using microtiter plates was modified for analysis of methamphetamine in sweat. After methamphetamine administration, sweat contains primarily parent methampbetamine. The immunoassay was determined to have crossreactivity relative to 100% for the methamphetamine (MA) calibrators; to 144% for methylenedioxymethamphetamine (MDMA); to 30% for d-amphetamine; to 21% for methylenedioxyamphetamine (MDA); and to 8% for I-methamphetamine. The optimum cutoff concentration for this modified assay was determined by receiver operating characteristic analysis to be 10 ng/mL amphetamine equivalents. At this cutoff concentration the assay had a diagnostic sensitivity of 84.5% and a diagnostic specificity of 93.2% versus gas chromatography-mass speclrometry (GC-MS). The positive predictive value at a prevalence of 50% was 86%. The intra-assay precision at 10 ng/mL was 9.9% (coefficient of variation, CV) and the interassay CV was 13%. Analysis of spiked patches at plus or minus 25 and 50% around the cutoff gave a percent positive threshold of approximately 50% at a cutoff of 10 ng/ml_ and a 95% confidence level for a positive result by the EIA between 15 and 20 ng/mL. Of 18 potential adulterants that might be injected into or under the patch, two (tile cleaner and cough syrup) caused a false-positive response by immunoassay. All results were confirmed by GC-MS. The clinical sensitivity and specificity of the overall analysis system (sweat collection and analysis) were 85 and 100%, respectively, using known methamphetamine dosing of volunteers (10, 20, and 25 rag) as the reference standard.
Introduction
Methamphetamine (MA) is excreted in sweat (1) . As for most drugs, the parent drug is the predominant analyte found in sweat (2, 3) ; MA, but little amphetamine (AM), is found in sweat after MA administration. MA appears in sweat within 24 h after *Address correspondence to Vina Spiehler, Ph.D., 422 Iustin Avenue, Newport Beach, CA 92663, E-mail: spiehleraa@aol.com. administration of MA in controlled studies and peaks within the first three days (4) . The MA concentrations in sweat are consistent with approximately 1-2% of the dose being excreted. In this study, a microtiter plate enzyme immunoassay for amphetamines was modified to detect MA in sweat.
Drugs in sweat were collected by the subjects wearing a Band-Aid| PharmChek TM Sweat Patch (Sudormed, Inc., Santa Ana, CA). Water (monomer and dimer forms), oxygen, carbon dioxide, and other gases pass freely through the polyurethane-adhesive covering of the patch, but transport of molecules larger than vapor phase isopropanol is prevented by the molecular pore structure (approximately 20~,) of the plastic membrane. MA persisted on the PharmChek sweat patch throughout the period of wear (7 days) with a slight decrease in amount 5-7 days after dosing. Any use of MA during patch wear was accompanied by the appearance of MA in sweat and the accumulation of increasing amounts of drug on the collection pad of the patch.
An immunoassay for screening for drugs in sweat must crossreact with the parent drugs and with the lipophilic rnetabolites excreted in sweat. It must have a dynamic range in the concentration range encountered with the sweat patch eluate and, for qualitative screening tests, employ a cutoff concentration appropriate for this application. In this study, receiver operating characteristic (ROC) analysis (5,61 was used to choose a cutoff calibration which optimized diagnostic sensitivity, specificity, and predictive value. Gas chromatography-mass spectrometry (GC-MS) analysis was used as the measure of presence of the drug (5) . In addition, the clinical sensitivity and specificity of the complete system (immunoassay screen and GC-MS confirmation) for detection of MA in sweat were calculated from known-dose studies (6) .
Materials and Methods

Specimen colleclion
Sweat and transdermal exudate were collected from human subjects using the PharmChek Sweat Patch which was worn on the skin by the subject for 1-7 days. The PharmChek Sweat Patch is a nonocclusive dressing consisting of a medical-grade cellulose blotter paper collection pad, covered by a thin polyurethane (0.001 in.) and acrylate adhesives membrane (Tegaderm TM Brand Transparent Dressing, 3M, St. Paul, MN). A nine-digit serial number is printed underneath the polyurethane for use in the chain of custody. The water component of sweat, vaporized by body heat, passes through the polyurethane; solids, salts, and drugs that are excreted in the sweat or that pass through the skin are trapped on the collection pad. The collection pad has a surface area of approximately 14 cm 2 and collects a minimum of 300 pL per day of insensible perspiration in a 22~ environment. Exercise, higher temperatures, or other factors that increase sweating increased the amount of sweat collected. Patches were worn by nonusers, by known drug users in controlled administration experiments, and by suspected drug users in field studies. All human subject studies were approved in advance by the respective institution's responsible committee.
At the end of the wear period, the collection pad was removed with disposable tweezers and placed in a 5-mL capped tube. The cellulose collection pad was eluted with 2.5 mL of 0.2M pH 5.0 acetate buffer with methanol (25:75). Pads and elution buffer were mixed for 30 rain on a slow speed reciprocating shaker at 150-200 cycles per min. Aliquots (50 pL) were screened by immunoassay; aliquots (0.5 mL) were analyzed for MA and AM by GC-MS. Eluates were refrigerated for up to 10 days to batch specimens. Specimens found to be positive by GC-MS were frozen at -5 to -15~ and stored.
Immunoassay
The STC Amphetamines Micro-plate EIA (STC Diagnostics, Bethlehem, PA) was a solid-phase competitive immunoassay employing horseradish peroxidase labeled with an MA derivative. Patch eluate (50 pL), control, or standard was added to each well along with labeled enzyme and allowed to incubate for 30 rain at room temperature. Following competition to bind to antibody sites immobilized on the surface of well, the wells were washed six times with distilled water each and aspirated. Substrate (3,3',5,5'-tetramethylbenzidine) added to each well, and the color produced after a 30-min incubation (stopped with 100 pL 2N sulfuric acid) was measured at an absorbance at 450 nm and at 630 nm. The absorbance was inversely proportional to the quantity of MA or other amphetamines in the specimen. The calibrators and controls in the kit consisted of sweat pad elution buffer with MA added at 0, 5, 10, and 50 ng/mL. Spiked-patch controls at 5 and 15 ng/mL were spiked with working solutions of MA in methanol and dried at ambient conditions for 1 h.
The limit of detection (LOD) was defined from the signal to noise ratio at the zero drug concentration as the mean zero absorbance (A0) minus the noise times three (LOD = A0-3SD) (7) . The LOD was determined by obtaining the absorbance values for 24 negative patches and calculating the standard deviation of the absorbance. The value for the standard deviation of the absorbance was then multiplied by three and subtracted from the mean absorbance value to obtain the absorbance at the limit of detection. The apparent MA concentration at the resulting absorbance is the limit of detection of the assay. The analytical sensitivity of the EIA around the cutoff concentration was assessed by analyzing replicate spiked samples at concentrations of 5, 7.5, 10, 20, and 25 ng/mL MA. The percent of positive responses was determined for each concentration. A positive response was an absorbance lower than the cutoff calibrator mean absorbance. The cutoff calibrator mean absorbance was determined for ten replicate calibrator samples, which were assayed after the calibration curve and before the spiked samples. Samples (n = 72) were run on seven different days at each concentration.
Crossreactivity was determined by analyzing suspected crossreactants at concentrations equal to the cutoff concentration and at ten times and one hundred times the cutoff concentration (Table I ). In addition, a series of common drugs was tested at concentrations of 10,000 ng/mL (Table II) . The percent crossreactivity was calculated as follows: apparent MA concentration from calibration curve % Crossreactivity = x 100 spiked concentration of compound Percentage displacement in the immunoassay measured from the negative calibrator was calculated from the following formula:
(absorbance negative calibrator-% Displacement = absorbance sample) x 100 absorbance negative calibrator For within-run and total precision a total of 280 collection pads were spiked with MA. Forty pads were prepared at concentrations of 2.5, 5, 7.5, 10, 15, 17.5, 20, and 25 ng/mL. MA in 100 pL methanol working solution was dropped onto the pads, and each pad was allowed to dry at ambient conditions for one hour. Two spiked pads from each concentration were extracted and analyzed by EIA every day for 20 days.
GC-MS
MA and AM were eluted off the sweat patch using methanol-acetate buffer. MA and AM were then extracted along with their deuterated analogues as internal standards into hexane-isoamyl alcohol, from 0.5 mL patch eluates alkalinized with 1M Na2CO3. The drugs were then back extracted into 500 ]JL 0.5M HCI, which was then alkalized with 500 pL 1M Na3CO3. Finally, they were re-extracted into n-butyl chloride, which was treated with derivatizing agent. Controls and standards consisted of 0, 4, 10, and 20 ng/mL each of MA and AM in extraction buffer. Internal standards consisting of 10 ng/mL each MA-d9 and AM-d6 were added to each sample before extraction.
The MA and AM were derivatized using 4-carbethoxyhexafluorobutyryl chloride (CB) at 65-75~ for 30 rain to form the acyl derivatives. The derivative extracts were evaporated under nitrogen at 50~ and then taken up in 30 IJL ethyl acetate and analyzed by GC-MS using selective ion monitoring , and 309 had to be present in abundance ratios of within 20% of the abundance ratios for the MA calibration standard. Drug ion abundances were normalized to 308 for MA. The quantitation ion for MA-d~ was 315 with ion 287 as a qualifier. To be judged positive for AM, ions 248, 266, and 294 had to be present with abundance ratios within 20% of the abundance ratios for the AM calibration standard. Drug ion abundances were normalized to 294 for AM. The quantitation ion for AM-d~ was 298 with ion 270 as a qualifier. For quantitation, the ratios of the 308/315 and the 294/298 ions for the drugs and the deuterated internal standard were compared with those ratios for the external standard calibration curve. The limit of quantitation (LOQ) for both MA and AM was 2 ng/mL of extraction fluid.
Adulteration study
Eighteen potential adulterants were studied for their effect on the immunoassay and the GC-MS (Table lII) . Spiked patches were prepared by applying 100 IJL of each adulterant to unworn patches, which were then allowed to air dry. The pads were then spiked with 75 ng MA and then incubated at 37~ for seven days. Pads were then extracted per standard procedures in the acetate buffer-methanol extraction buffer. Extracts were analyzed by th STC Amphetamines EIA and by GC-MS.
Vicks inhaler study
Subjects in this study had nine patches applied to their skin on the wear sites prescribed for wear. Following a one-day wear period, one patch was removed for baseline measurements. At that time the volunteer subject was provided with two Vicks | inhalers containing 50 mg desoxyephedrine each. Subjects were instructed by the protocol to use the inhalant on both nostrils once every 2 h for 8 h each day for seven days. Patches were removed each day. On the eighth and tenth days a patch was removed and replaced by a fresh patch. All of these patches were removed on day twelve. Patches were analyzed by immunoassay.
ROC analysis
The number of true positives (TP), false negatives (FN), false positives (FP), and true negatives fiN) was determined for six putative cutoff concentrations (at 2.5, 5, 10, 15, 20, and 50 ng/mL AM equivalents) by comparison of the immunoassay result with the result by GC-MS. A sample was considered a true positive if both the immunoassay and the GC-MS results were in concordance, that is, they were both positive for amphetamines (MA present above the putative cutoff concentration). A sample was considered a true negative if both tests were negative for amphetamines. Samples for which the immunoassay was positive (absorbance below the mean of the cutoff calibrator absorbance) but the GC-MS result revealed MA concentrations to be negative or below the LOQ were defined as false positives. Samples for which the immunoassay result was negative (absorbance above the mean of the cutoff calibrator) but the GC-MS result showed MA concentrations above the LOQ of the assay were defined as false negatives (FN). Sensitivity and Specificity were calculated according to the following formulas (8):
Sensitivity = TP/(TP + FN) Specificity = TN/(TN + FP)
Sensitivity was plotted versus 1-specificity for the six possible cutoff concentrations to obtain ROC curves (5). Positive predictive value was calculated from the following formula:
Positive predictive value = sensitivity x prevalence [(1-specificity) x (l-prevalence)] + (sensitivity x prevalence)
Results
Analytical precision and accuracy
The limit of detection (LOD), which was calculated from the mean absorbance minus three times the SD of the zero calibrators (n = 24), was found to be 3.69 ng/mL.
Crossreactivity of the enzyme immunoassay at 10 ng/mL was 144% for MDMA, 30% for d-AM, 21% for MDA, 7.3% for 1-MA, and 23% for I-AM relative to 100% for the MA calibrators. However, for all but MDMA, these apparent concentrations were below the LOD of the assay. The crossreactivity for AM and the sympathomimetic amines (ephedrine 22%, phenylpropylamine, 29%, and pseudoephedrine 31% at 10 ng/mL) were not parallel to the calibration curve for MA and fell to 2-3% at 100 ng/mL and to 0.3-0.55% at 1000 ng/mL (Table I) . Although the crossreactivity appeared to be great at 10 ng/mL, the responses were less than the LOD and therefore the lower value is probably more reliable. None of the 38 common drugs or chemicals tested at 10,000 ng/mL showed any crossreactivity in the assay (Table II) .
The analytical sensitivity of the EIA around the cutoff concentration was assessed by analyzing replicate spiked samples at concentrations of 5, 7.5, 10, 20, and 25 ng/mL. The percent positive response graphed for each concentration yielded the threshold response graph shown in Figure 1 . The slope of the curve was the qualitative response of the EIA. From this slope a sample containing exactly 10 ng/mL MA had a 50% probability of being screened positive.
The intra-assay precision of the absorbance averaged over four days (n = 15 each day) was 10.9% for the 10 ng/mL calibrators, 9.8% at 5 ng/mL, 9.8% at 7.5 ng/mL, 9.9% at 10 ng/mL, 8.7% at 20 ng/mL, and 12.9% at 25 ng/mL. The interassay precision of the absorbance over 20 days was 10.2% at 0 ng/mL, 17% at 5 ng/mL, 13% at 10 mL, and 14% at 50 ng/mL.
Diagnostic accuracy
As seen in Figure 2 , for 229 specimens from 50 subjects, using GC-MS as the reference standard for true presence or absence of MA, the false-positive rate was greater above a cutoff of 5 ng/mL, and the false-negative rate was greater above a cutoff of 10 ng/mL. From the ROC curve (Figure 3) , the maximum sensitivity and specificity fell between the cutoffs of 10 ng/mL and 5 ng/mL. A cutoff of 10 ng/mL was chosen as the more conservative. Using a cutoff concentration of 10 ng/mL, the diagnostic sensitivity of the immunoassay was 84.5% (131/155), and the diagnostic specificity was 93.2% (69/74). For these values, the predictive value for a positive immunoassay result for MA in sweat at 50% prevalence was 86.1%, and the negative predictive value was 75%. This positive predictive value was in the range reported for positive predictive values of commercially available laboratory immunoassay tests (radioimmunoassay and EIA) for AM in urine (9) . This range was 82.9% to 94.1% at a prevalence of 50%.
Adulterants
The qualitative response to MA spiked onto a unworn patch after treatment with 18 potential adulterants that might be injected into or under the patch, is shown in Table III . Two substances (tile cleaner and cough syrup) caused a false positive response of the immunoassay. Two adulterants reduced immunoassay response to spiked drug by 25% or more in re- peated trials (sugar water and mouthwash) and caused a false negative. None of the substances caused false results by GC-MS; therefore, an immunoassay false positive because of these adulterants would not be reported positive after GC-MS confirmation.
Vicks inhaler
Use of a Vicks inhaler (l-desoxyephedrine) for the maximum recommended dose of 160 rag/day or 1.12 g total (7 days, 8 applications/day, 20 rag/application) resulted in borderline positives by immunoassay on days four through ten. Patches from days six to ten for the first subject tested 14, 10, 14, and 10 ng/mL AM equivalents by the EIA; patches from the second subject on days four through ten contained 10, 15, 17, 6.7, 11, and 19 ng/mL AM equivalents by EIA. GC/MS LOQ 2 ng/mL Methamphetamine 
Discussion
Validation of an immunoassay for use with alternate specimens requires that the immunoassay crossreact with the analytes found in the biological specimen, that it have a dynamic range within the concentrations of drug found, and that it be accurate in the detection of drug present. Accuracy for a qualitative test is validated by demonstrating that the cutoff concentration has the required diagnostic sensitivity and specificity to yield a useful predictive value in the populations encountered in screening situations. Obviously, in the absence of established cutoff values, diagnostic sensitivity and specificity considerations should direct the choice of a cutoff. In this study, ROC curves, obtained using GC-MS for MA as the reference standard as to the presence of the drug, indicated either 5 ng/mL or 10 ng/mL as the best cutoff. The latter (10 ng/mL) was the more conservative choice because it minimized the false positives at the expense of slightly increased false negatives.
Before application of the patch, the skin was prepared with an isopropyl alcohol wipe. This alcohol preparation removed dirt and natural skin oils and substances used on the skin such as lotions and creams, as well as any contaminants that may be applied to the skin to intentionally adulterate the patch. Because the polyurethane layer is impermeable to molecules larger than dimer water (MW 36), contaminants and solvents applied to outside of the patch do not cross the polyurethane layer to reach the collection pad. Some solvents and treatments might destroy the polyurethane layer, but these are noticeable by the holes that appear in the polymer. Substances could be injected into or under the collection pad with a needle and syringe. Exposure of the skin under the patch for more than a few minutes to many of the substances studied for adulteration would lead to visible inflammation of the skin and dis-comfort for the subject. One-hundred microliters liquid drain cleaner, bleach, tile cleaner, or spot remover produced painful and visible trauma to the skin even when contact was sustained for less 30 rain. The drug-treatment professional who removes the patches from subjects who are being monitored for drug use would be trained to recognize the inflammation caused by adulterant substances injected into patches and note it on the chain of custody.
However, in forensic applications, no immunoassay positive result would be reported without confirmation. The complete system, sweat collection patch and analysis, was evaluated using known dosing of MA from controlled-dosing studies (4) . The concordance of positive and negative GC-MS results for MA taken after 24 h of wear on sweat patch specimens with known drug doses given to patch-wearing subjects (n = 64) is as follows: 47 positives and 8 negatives when MA was administered; no positives and 64 negatives when MA was not administered. From these data, the clinical sensitivity of the overall system is 85% (47/55), and the clinical specificity is 100% (64/64). The predictive value of a positive result (PPV) reported for MA in sweat with this system would approach 100% and the negative predictive value (NPV) was 87% at 50% prevalence. PPV and NPVwere 100% and 95%, respectively, at 25% prevalence and 100% and 98%, respectively, at 10% prevalence (8) . The concordance data were obtained from 119 patch specimens from 30 subjects who participated in controlled dosing studies. Drug doses given were 10, 20, and 25 mg MA HCI (Desoxyn) administered orally. These doses are in the range of MA administered medically (10) and are probably lower than a street drug dose. Therefore, these results indicate the ability of the sweat collection and analysis system to detect MA in sweat after minimal MA use.
Conclusion
A useful application of this sweat patch technology was for monitoring drug treatment and drug-free compliance. This has been done by urine testing, but success depends on the frequency of urine testing. Typical drugs of abuse are cleared from urine in 2-3 days following a single exposure. This requires urine testing to be performed a minimum of every 2-3 days for accurate monitoring of drug use. Unfortunately, testing this frequently would overwhelm most testing budgets. The data presented in this paper suggest that a patch, worn for a week, effectively monitored a subject's use of amphetamines during that week. This became very cost-effective as a single specimen and a single analysis provided information continuously over a week of monitoring. It was also possible that this technology had a positive effects on subjects. If the subject realizes that the patch can collect and retain evidence of even a single drug exposure, this understanding may deter drug use. Previous papers suggest that the patch works equally well for cocaine and opiates (2, 3) . Future papers will present similar data for PCP and marijuana.
